Compare AbbVie Inc (ABBV) vs Zillow Group Inc Class A (ZG) Price & Performance

AbbVie (ABBV) trades at $252.63, down 0.84% on the day, with a bullish technical signal and strong support at $248. The stock shows robust fundamentals with revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed to 5.79%. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional accumulation, reinforcing growth prospects beyond Humira's patent expiry.

Outlook remains positive with a consensus price target of $266.33 (5.4% upside), supported by 68% analyst buy ratings. Key opportunities include immunology drugs Skyrizi and Rinvoq driving growth, but risks involve patent cliffs in the 2030s, high debt levels, and regulatory pressures on drug pricing. The stock offers a resilient dividend with recent increases, appealing for income-focused investors amid sector volatility.

Zillow Group (ZG) trades at $32.69, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $2.58 billion for 2025 with a net income of $23 million, marking a return to profitability after losses in prior years. Recent news is dominated by multiple securities class action lawsuits alleging anticompetitive conduct, creating significant headline risk.

The investment outlook is clouded by legal overhangs despite positive earnings beats and a consensus analyst price target of $57.80 implying substantial upside. Key risks include the outcome of litigation and the sustainability of recent margin improvements. The high P/E ratio of 131.8 suggests growth expectations are already priced in, demanding flawless execution.